• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

FDA, seeking time for phase 4 talks, delays decision on Valneva's chikungunya vaccine...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 14, 2023 at 10:42: AM
via The FDA is making Valneva wait. Two weeks from the original deadline, the agency has pushed back its decision on whether to approve Valneva’s chikungunya virus vaccine candidate by three months.

article source
 

<



Similar threads

cafead
Xspray, seeking FDA approval for its Sprycel competitor, settles patent lawsuit with BMS
Replies
0
Views
155
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA: iRhythm targeted heart monitor at ‘high-risk’ patients without seeking clearance
Replies
0
Views
112
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Replies
0
Views
188
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck, seeking XI factor in race with Bayer, gets FDA fast-track tag for anticoagulant
Replies
0
Views
171
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA spells out the rules and restrictions for states seeking to import drugs from Canada
Replies
0
Views
132
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote